title: A quarter of a century experience with sleeve lobectomy for non-small cell lung cancer.
abstract: OBJECTIVE
  Sleeve lobectomy represents an effective and widely accepted surgical therapy for non-small cell lung carcinoma (NSCLC). We sought to review our experience in terms of mortality, early and late morbidity, and long-term survival evaluating the technical progresses overtime.
  
  
  METHODS
  From 1980 to 2005, 199 patients underwent sleeve lobectomy. Pathology revealed 167 (83.9%) squamous carcinomas, 23 (11.6%) adenocarcinomas, 7 (3.5%) large cell and 2 (1%) adenosquamous carcinomas. In 39 (19.6%) patients a vascular procedure was associated. Nineteen (9.5%) patients had preoperative radiotherapy, 14 (7%) preoperative chemotherapy and 10 (5%) chemoradiotherapy.
  
  
  RESULTS
  Overall postoperative mortality was 4.5% (n=9) and morbidity was 17.9% (n=34). Preoperative radiotherapy was identified as a significant risk factor for perioperative mortality (OR: 5.34, 95% CI: 1.16-24.47; p=0.03) and early anastomotic complications (OR: 3.73, 95% CI: 1.01-13.68; p=0.04). Overall 5-year survival rate was 39.7% and stage-by-stage analysis did not reach a significant survival difference. With growing skills the number of procedures, associated angioplasty and difficult sleeves (such as sleeve bilobectomy) increased. Also in term of mortality, in the last 10 years we had 0.8% of mortality rate.
  
  
  CONCLUSIONS
  Sleeve lobectomy is a safe and effective therapy for selected patients with NSCLC. Vascular procedures and the use of induction chemotherapy did not increase mortality and morbidity; otherwise, the use of preoperative radiotherapy is not recommended. Overtime trend showed a significant lower mortality in the last period. This emphasises the importance of a learning curve and encourages the performance of this procedure in experienced centres.
authors.affiliation: Department of CardioThoracic and Vascular Sciences, Division of Thoracic Surgery, University of Padova, Medical School, Padova, Italy. federico.rea@unipd.it
authors.forename: Federico
authors.initials: F
authors.lastname: Rea
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Marulli
authors.forename: Marco
authors.initials: M
authors.lastname: Schiavon
authors.forename: Andrea
authors.initials: A
authors.lastname: Zuin
authors.forename: Abdel-Mohsen
authors.initials: AM
authors.lastname: Hamad
authors.forename: Giovanna
authors.initials: G
authors.lastname: Rizzardi
authors.forename: Egle
authors.initials: E
authors.lastname: Perissinotto
authors.forename: Francesco
authors.initials: F
authors.lastname: Sartori
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D003131:Combined Modality Therapy; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011013:Pneumonectomy / Q000009:adverse effects / Q000379:methods*; D011651:Pulmonary Artery / Q000601:surgery; D016896:Treatment Outcome